Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CTI

- PMLiVE

NICE backs BMS-Pfizer’s Eliquis in atrial fibrillation

Final draft guidance recommends the drug for common heart condition

- PMLiVE

Global academic research alliance to speed drug development

Includes centres from UK, US, Canada, Germany and Belgium

- PMLiVE

Pfizer gets CHMP backing for leukaemia drug bosutinib

Provides option for patients resistant to tyrosine kinase inhibitors

- PMLiVE

IQWiG finds some value in Pfizer’s Inlyta

Cost effectiveness body decides cancer drug has benefits over Bayer's Nexavar

- PMLiVE

Pfizer enters ADHD market with Quillivant XR launch

Gained rights last November as part of NextWave acquisition

- PMLiVE

Gilead $1bn antibody deal with MacroGenics

Joins Boehringer and Servier in use of US biotech’s DART technology

- PMLiVE

Biotech challenging big pharma for M&A deals

Purchasing power growth of 'big biotech' outpaces pharma sector

- PMLiVE

Sanofi enters vaccines partnership with Sutro

Will develop products for two undisclosed targets

Pharma deals during December 2012

Deal Watch: Major pharma collaborations, acquisitions and agreements in the past month

- PMLiVE

Pfizer acquires spinal muscular atrophy research programme

Gains rights to drug candidate RG3039 in deal with Repligen that could be worth up to $70m

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

- PMLiVE

FDA clears six new drugs in time for the new year

Brings 2012 tally to 39 – the highest for more than 15 years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links